HF3228 Summary

• Establishes the Prescription Drug Affordability Commission with seven members to protect consumers and healthcare stakeholders from excessive prescription drug costs through review and regulation of drug pricing.

• Requires drug manufacturers to notify the commission of brand name drugs/biologics with WAC increases exceeding 10% or $10,000 in a 12-month period, biosimilars priced less than 15% below reference biologics, and generic drugs with $100+ price increases following 200% increases.

• Authorizes the commission to conduct affordability reviews of reported drugs and establish maximum reimbursement levels for drugs creating affordability challenges, applying to all public and private purchases in the state.

• Establishes an 11-member Prescription Drug Affordability Advisory Council representing patients, providers, employers, health plans, manufacturers, and researchers to advise the commission on drug cost issues.

• Prohibits ERISA plans and Medicare Part D plans from being required to comply with commission decisions, though providers must bill all payers no more than the established maximum reimbursement level.